Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 12 March 2025 - 16:01

Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2288

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters